$Neuronetics (STIM.US)$ NEWS New Publication in Brain Stimul...
NEWS
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
Neuronetics, Inc. (NASDAQ: STIM) announces significant clinical findings in Brain Stimulation journal regarding the predictive value of early symptom improvement in major depressive disorder (MDD) patients undergoing transcranial magnetic stimulation (TMS) treatment. Lack of early improvement does not predict final non-response status, emphasizing the importance of completing the full 36-session treatment regimen for maximum benefit.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
579Followers
65Following
3673Visitors
Follow